Octagon's ViewPoint Supports EU Module 1 Specification
Octagon Research Solutions announced support for recent European Union requirements for electronic Common Technical Document (eCTD) Submissions with the general availability of the following new versions of its eCTD product suite:
- ViewPoint v.3.12.0
- Octagon’s eCTD Viewer, v.2.6.0
- Octagon’s eCTD Validator, v.2.6.0
A key feature of the new releases includes support across all three products for eCTD EU Module 1 Specification, version 1.4.
The new product releases include support for updated attributes, naming conventions and checksum information as detailed in the 1.4 specification. The European Union applies the eCTD Specification in the European region as defined by the ICH M2 Working Group and completes it with the EU Module 1 specification.
“Support for the latest EU specification is critical to Octagon’s global clients who are submitting eCTD applications in the European Union,” noted Kirk Gallion, president, Octagon Research Solutions, Inc. “We are committed to supporting these updates as the industry continues to realize the global benefits of electronic submissions in general and the eCTD in particular.”
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
